Angiotensin II type 1 receptor blocker-induced immune thrombocytopenia: a case report

Journal of Medical Case Reports

David Schnee¹  Nikhil Bilkha¹  Dhiren K Patel² 

[1] VA Boston Healthcare System, 150 South Huntington Avenue, Boston, MA 02130, USA;Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115, USA

关键词: Angiotensin receptor blocker;    Valsartan;    Losartan;    Adverse drug reactions;    Drug-induced thrombocytopenia;   

Others  :  1181136
DOI  :  10.1186/1752-1947-7-183

 received in 2013-02-12, accepted in 2013-05-28,  发布年份 2013

【 摘 要 】

Introduction

The development of thrombocytopenia after a dose increase in losartan and subsequently after switching the patient to valsartan is reported.

Case presentation

A 61-year-old Caucasian man presented with epistaxis and gingival bleeding of three weeks duration. Laboratory evaluation revealed a hemoglobin level of 144g/L, a leukocyte count of 16.2×10⁹ cells/L (72.51% neutrophils, 20.1% lymphocytes, 6.8% monocytes, 0.4% eosinophils, 0.2% bands), and a platelet count of 15.0×10⁹ cells/L. Flow cytometry of his peripheral blood showed normal CD4:CD8 ratio and no evidence of any lymphoproliferative disorder. A peripheral smear showed decreased platelets with a few areas of clumping. Four weeks before presentation to the emergency room, his losartan dose was increased to 100mg once daily due to continuously elevated blood pressure readings. He had been maintained on losartan 50mg once daily for five years and previous routine laboratory measurements revealed a baseline platelet count of 248.0×10⁹ cells/L.

The patient began receiving an oral prednisone taper and his platelet count returned to a stable value of >200×10⁹ cells/L. Because there was no other probable cause, he was thought to have developed immune thrombocytopenia from the increased losartan dose. Losartan was discontinued and one week later he was switched to valsartan 160mg once daily.

Forty-seven days after starting valsartan, the patient presented once again to the emergency room with intermittent epistaxis and gingival bleeding while brushing his teeth of two weeks duration. Laboratory measurement revealed a platelet count of 37×10⁹ cells/L. Valsartan was held and another prednisone taper was initiated. The patient’s platelet count recovered upon valsartan discontinuation and in four weeks, his platelet count improved to 214×10⁹ cells/L.

Conclusions

A 61-year-old Caucasian man developed immune thrombocytopenia after an increase in losartan dose and developed immune thrombocytopenia again after he was switched to valsartan.

【 授权许可】

   
2013 Patel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Zondor SD, George JN, Medina PJ: Treatment of drug-induced thrombocytopenia. Expert Opin Drug Saf 2002, 1:173-180.
• [2]Ada S, Yalamanchili M, Friedenberg W: Immune thrombocytopenia after losartan therapy. Ann Intern Med 2002, 137:704.
• [3]Edarbi [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2011.
• [4]Atacand [package insert]. Wilmington, DE: AstraZeneca, LP; 2012.
• [5]Teveten [package insert]. North Chicago, IL: Abbott Laboratories; 2012.
• [6]Avapro [package insert]. New York, NY: Bristol-Myers Squibb Sanofi-Synthelabo Partnership; 2012.
• [7]Cozaar [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2011.
• [8]Benicar [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2009.
• [9]Micardis [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2012.
• [10]Diovan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2012.
• [11]Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
• [12]Michel DJ, Knodel LC: Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm 1986, 43:1709-1714.
• [13]George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T: Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Int Med 1998, 129:886-890.
• [14]Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:851-869.
• [15]Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1961.
• [16]Aster RH, Bougie DW: Drug-induced immune thrombocytopenia. N Engl J Med 2007, 357:580-587.
• [17]George JN, Aster RH: Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program 2009, 1:153-158.
• [18]Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994, 84:3691-3699.
• [19]Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet 2000, 335:637-645.